Algernon Pharmaceuticals Inc (AGNPF)

[tcm55]

This article talks about existing IPF drugs and their deficiencies. It sounds to me like NP-120 compounds are targeting some of the issues described here. Maybe someone qualified could comment. 2 months old but informative about IPF / COVID etc...

" However, this hypothesis must be advanced with important caveats, all of which need to be addressed if existing antifibrotic agents are to be applied in the current pandemic.
dysregulation of SARS-CoV-2 infection, nor can they be expected to attenuate the prothrombotic aspects of this complex pathogenic process. If antifibrotic therapy is to have a role, it is likely to take the form of inclusion in combination regimens, once effective anti-inflammatory treatments have been identified. Combination therapy could, in principle, address major anti-inflammatory and antifibrotic pathways while attenuating their fibrotic consequences.

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30225-3/fulltext